3D Medicines (HKSE:01244) Short-Term Capital Lease Obligation : HK$25.4 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Short-Term Capital Lease Obligation?

3D Medicines's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$25.4 Mil.

3D Medicines's quarterly Short-Term Capital Lease Obligation increased from Dec. 2022 (HK$12.6 Mil) to Jun. 2023 (HK$24.4 Mil) and increased from Jun. 2023 (HK$24.4 Mil) to Dec. 2023 (HK$25.4 Mil).

3D Medicines's annual Short-Term Capital Lease Obligation declined from Dec. 2021 (HK$15.6 Mil) to Dec. 2022 (HK$12.6 Mil) but then increased from Dec. 2022 (HK$12.6 Mil) to Dec. 2023 (HK$25.4 Mil).

3D Medicines Short-Term Capital Lease Obligation Historical Data

The historical data trend for 3D Medicines's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Short-Term Capital Lease Obligation Chart

3D Medicines Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

4.49

15.62

12.63

25.40

3D Medicines Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial			15.62	-	12.63	24.42	25.40

3D Medicines Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

3D Medicines Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

3D Medicines (HKSE:01244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN

Website

https://www.3d-medicines.com

3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.

Executives

Gong Zhaolong	2101 Beneficial owner
Zhu Pai	2101 Beneficial owner
Dragon Prosper Holdings Limited	2101 Beneficial owner
Simcere Pharmaceutical Group Limited	2101 Beneficial owner
Gong Zhaolong	2501 Other
Immunal Medixin Us Limited	2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership)	2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd.	2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.)	2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership)	2201 Interest of corporation controlled by you
Zhu Jinqiao	2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines